As the world enters its third year of the COVID-19 pandemic, individuals with diabetes
have faced particular challenges from the virus. A deleterious bidirectional relationship
exists between the two disorders, with heightened inflammatory, immunologic, and cellular
mechanisms leading to a more severe illness and increased morbidity and mortality.
Tight glucose control, though necessary, is hampered by physical restrictions and
difficulty accessing health care. Novel glucose-lowering medications may provide unique
benefits in this regard. It is imperative that multi-pronged efforts be prioritized
in order to reduce adverse outcomes in patients with diabetes at risk for COVID-19.
